Yisheng Pharma's Rabies Vaccine Passes Phase I Test
January 05, 2016 at 05:00 AM EST
Yisheng Biopharma, a Beijing-headquartered vaccine company, announced positive results from a Phase I trial of its therapeutic PIKA-adjuvant rabies vaccine. The Yisheng product was well tolerated and caused a faster seroconversion rate than the standard rabies vaccine control. The PIKA adjuvant uses a novel double-strand RNA analog (PIKA), which acts as a toll-like receptor-3 (TLR-3) agonist to activate an innate immune response. Yisheng's vaccine requires only three injections in seven days, as opposed to the usual regimen of four shots over 14 days. More details.... Share this with colleagues: // //